

THURSDAY, JUNE 30, 1988

SYMPOSIUM E — 8:30 - 11:00 A.M.

Molecular Mechanisms of Abused Substances

Chairperson: Leo G. Abood

- 8:30 *Molecular Mechanism of Interactions of Hallucinogens and Indole Derivatives at 5-HT Receptors*
Harel Weinstein, Mt. Sinai Medical Center, New York, NY
- 9:00 *Regulatory Mechanisms in Endogenous Opioid Systems*
Huda Akil, University of Michigan, Ann Arbor, MI
- 9:30 *Molecular Mechanisms of Drug Reinforcement: Current Status*
James E. Smith, Louisiana State University Medical Center, Shreveport, LA
- 10:00 *Cannabinoid Action in the Central Nervous System*
Billy R. Martin, Medical College of Virginia, Richmond, VA
- 10:30 *An Assessment of the Involvement of Second Messenger-Transductive Systems in the Action of Abused Drugs*
Leo G. Abood, University of Rochester Medical Center, Rochester, NY

OPEN PAPERS D — 8:30 - 11:30 A.M.

Clinical Pharmacology and Treatment

Chairpersons: Herbert D. Kleber and Jack H. Mendelson

- 8:30 *Topographic Mapping of Quantitative EEG Variables in Chronic Heavy Marijuana (THC) Users*
F. A. Struve and J. Straumanis, Louisiana State University Medical School, Shreveport, LA
- 8:45 *Ethanol Effects on Marijuana-Induced Intoxication and Electroencephalographic Activity*
S. E. Lukas, J. H. Mendelson, J. Henry, L. Amass and A. Budson, Alcohol and Drug Abuse Research Center, McLean Hospital, Belmont, MA, and Harvard Medical School, Boston, MA
- 9:00 *Dependence upon Anabolic Steroids*
F. Tennant, Community Health Projects Medical Group, West Covina, CA
- 9:15 *Experimental Analysis of Short-Term Memory Impairments Produced by Triazolam (TZ) and Pentobarbital (PTB) in Healthy Volunteers*
J. D. Roache, T. Kirk and R. R. Griffiths, University of Texas Health Science Center, Houston, TX and Johns Hopkins University School of Medicine, Baltimore, MD
- 9:30 *Evaluation of the Abuse Potential of Methocarbamol in Man Compared to the Benzodiazepine Lorazepam*
J. J. Guarino, K. L. Preston, William T. Kirk and R. R. Griffiths, Johns Hopkins University School of Medicine, Baltimore, MD
- 9:45 *Developmental Time Course of Acute Opioid Physical Dependence in Humans*
S. J. Heishman and M. L. Stitzer, Johns Hopkins University School of Medicine and Francis Scott Key Medical Center, Baltimore, MD
- 10:00 *Predictors of Continued Opiate Use during the Course of a 90-Day Methadone Detoxification*
M. Y. Iguchi, M. L. Stitzer and I. A. Liebson, Johns Hopkins University School of Medicine and Francis Scott Key Medical Center, Baltimore, MD
- 10:15 *Opioid Detoxification Using Buprenorphine*
T. R. Kosten, J. Krystal, D. S. Charney, L. Price, C. I. Morgan and H. D. Kleber, Yale University School of Medicine, New Haven, CT
- 10:30 *Difficulties in a Clinical Application of Methadone Dose Contingency Contracting*
D. Nollimal and T. J. Crowley, Addiction Research and Treatment Services, University of Colorado Health Sciences Center, Denver, CO

2021569287

THURSDAY, JUNE 30, 1988

- 10:45 *A Quantitative Measure of Substance Abuse Treatment: The Treatment Services Review*
A. T. McLellan, A. Alterman, W. Burke, G. Parikh, D. Zanis and A. Bragg, University of Pennsylvania, VA Medical Center, Philadelphia, PA
- 11:00 *Relationship of Client Characteristics with Non-Compliance in Methadone Maintenance Treatment*
A. Tommasello, K. Nilsen and J. Ball, University of Maryland School of Pharmacy, Baltimore, MD
- 11:15 *Comparative Effectiveness of Reducing Cocaine Abuse among Methadone Patients Using Phase Lowering or Dose Reduction*
M. McCarty and R. I. H. Wang, Veterans Administration Medical Center, Milwaukee, WI

LUNCH — 11:30 A.M.

POSTER SESSION B — 1:00 - 2:30 P.M.

40. *Toxicology Screening in Acute Spinal Cord Injury*
S. Schnoll, A. W. Heinemann, M. Brandt, R. Maltz and M. Keen, Medical College of Virginia, Richmond, VA
41. *Effects of Ethanol on Regional Cerebral Metabolism and Mood*
H. de Wit, J. Metz, J. B. Brunner and M. D. Cooper, University of Chicago, Chicago, IL
42. *Comparison of the Effects of Secobarbital and Diazepam on the Acquisition of Response Sequences in Humans*
S. T. Higgins and M. L. Stitzer, University of Vermont, Burlington, VT and Johns Hopkins University School of Medicine, Baltimore, MD
43. *Successful Transfer to Buprenorphine in a Patient on Morphine*
J. R. Hughes, W. K. Bickel and S. T. Higgins, University of Vermont, Burlington, VT
44. *Behavioral Effects of Benzodiazepine Antagonists in Rats Treated Chronically with Diazepam*
I. Lucki and R. F. Kucharik, University of Pennsylvania School of Medicine, Philadelphia, PA
45. *Urinary Excretion of Cocaine, Benzoylecgonine and Ecgonine Methyl Ester in Humans*
J. Ambre, T. I. Ruo, J. Nelson and S. Belknap, Northwestern University Medical School, Chicago, IL
46. *Tolerance to Cardiovascular Effects of Nicotine in Humans*
K. A. Perkins, L. H. Epstein, R. L. Stiller, J. R. Jennings, B. L. Marks and R. G. Jacob, Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh, PA
47. *Antagonist Actions of the Opioid Analgesic Nalbuphine in Humans*
G. E. Bigelow, K. L. Preston and I. A. Liebson, Johns Hopkins University School of Medicine, Baltimore, MD
48. *Psychiatric Disorders in Twin and Non-Twin Alcoholics*
L. Briskin, N. Anderson, D. Svikis and R. Pickens, University of Minnesota, Minneapolis, MN, Johns Hopkins University, Baltimore, MD, and NIDA, Rockville, MD
49. *The Effect of Intrathecally Administered Opioids and Antagonists on Blood Sugar Levels*
U. Estrada, F. Lux and W. L. Dewey, Medical College of Virginia, Richmond, VA
50. *Methadone Maintenance for AIDS-Affected IV Drug Users: Psychiatric Factors and Outcome Three Months into Treatment*
S. L. Baki, J. L. Sorensen, C. Coates and D. R. Gibson, University of California School of Medicine and San Francisco General Hospital, Substance Abuse Services, San Francisco, CA
51. *Drug Use Patterns by FHP and FHN College Males*
M. E. McCaul, D. S. Svikis, J. S. Turkkan and G. E. Bigelow, Johns Hopkins University School of Medicine, Francis Scott Key Medical Center, Baltimore, MD

2021589288

52. *Conditioned Abstinence and Conditioned Tolerance in Human Opiate Abusers*
R. N. Ehrman, J. W. Ternes, J. M. Holahan and C. P. O'Brien, VA Medical Center,
University of Pennsylvania, Philadelphia, PA
53. *Comparative Effects on Body Weight, Food Intake and Body Temperature in Rats on Withdrawal from the Putative Serotonergic Anxiolytic, Ipsapirone, and from Chlordiazepoxide*
A. J. Goudie, M. Leathley and J. McNally, University of Liverpool, Liverpool, U.K.
54. *Signs and Symptoms from Nicotine Abstinence*
D. K. Hatsukami, University of Minnesota, Minneapolis, MN
55. *Phenobarbital as well as Pentobarbital Enhances ³H-GABA Binding in Rat Forebrain Membranes*
J. A. Richter, Indiana University School of Medicine, Indianapolis, IN
56. *Enhancement of the Rate-Altering Effects of Morphine following Chronic Naltrexone Treatment*
A. M. Young and S. R. Mattox, Wayne State University, Detroit, MI
57. *Characterizing Future Smokers*
R. B. Coombs, S. Li, L.T. Kozlowski, J. C. Robinson and W. S. Rickert, Addiction Research Foundation and Labstat Inc., Toronto, Ont. Canada
58. *Acute Effects of Diazepam (DZP) in Rhesus Monkeys as Measured by Performance in a Battery of Complex Operant Tests*
M. G. Paule and G. E. Schulze, National Center for Toxicological Research, Jefferson, AR
59. *Normal and Abnormal Natural Killer (NK) Activity in Methadone Maintenance Treatment Patients*
M. Ochshorn, M. J. Kreek, E. Khuri, L. Fahey, J. Craig, M. C. Aldana and H. Albeck, The Rockefeller University, and Cornell Medical College, New York, NY
60. *Naloxone Induced Analgesia and Augmentation of Catalepsy and Analgesia Induced by Morphine is Contingent upon Exposure to Hot Plate under the Influence of Naloxone*
D. M. Knoke, C. X. Poulos, A. D. Lê and H. Cappell, University of Toronto and Addiction Research Foundation, Toronto, Ont., Canada
61. *Eighteen Month Outcomes of School- and Combined School- and Family-Based Preventive Interventions*
B. H. Bry, D. M. Greene, C. Schutte and E. Turk, Rutgers University, Piscataway, NJ
62. *Drug-Seeking Behavior and Morphine-Induced EEG Responses in Morphine Post-Addict Rats Chronically Treated with Ethylketocyclazocine (EKC)*
G. A. Young and N. Khazan, University of Maryland School of Pharmacy, Baltimore, MD
63. *Behavioral Effects in the Mouse during and following Withdrawal from Repeated Ethanol and Nicotine Administration*
E. S. Onaivi and B. R. Martin, Medical College of Virginia, Richmond, VA
64. *Dispositional Interactions of Cocaine (COC) with Delta-9-Tetrahydrocannabinol (THC) in the Rat*
S. Husain, University of North Dakota School of Medicine, Grand Forks, ND
65. *Chronic Opioid Antagonist Treatment Produces Supersensitivity to the Analgesic Effects of Morphine in Opioid-Sensitive and Insensitive Mice*
B. C. Yoburn, S. P. Kreuscher and V. Sierra, St. John's University, Jamaica, NY
66. *Desipramine Treatment of Cocaine Abuse in Methadone Maintenance Patients*
I. Arndt, L. Dorozynsky, G. Woody, A. T. McLellan and C. P. O'Brien, VA Medical Center, University of Pennsylvania, Philadelphia, PA
67. *Opioids Regulate Neurotumor Cell Growth in Tissue Culture*
P. J. McLaughlin and I. S. Zagon, The Milton S. Hershey Medical Center, Pennsylvania State University, Hershey, PA
68. *Comparison of the Effects of Buspirone and Chlordiazepoxide on Comparable Rates of Punished and Unpunished Responding*
S. Izenwasser and S. I. Dworkin, Louisiana State University, Shreveport, LA
69. *Posttreatment with Inhibitors of Prostaglandin Synthesis Antagonizes Ethanol-Induced Sleep Time*
G. I. Elmer and F. R. George, University of Maryland School of Pharmacy and NIDA Addiction Research Center, Baltimore, MD

2021589289

THURSDAY, JUNE 30, 1988

70. *Discriminative Stimulus Effects of Butorphanol, Nalbuphine, Naloxone and Hydromorphone in Opioid-Dependent Human Volunteers*
K. L. Preston, G. E. Bigelow and I. A. Liebson, The Johns Hopkins University School of Medicine, Baltimore, MD
71. *Rapid Eye Screening to Detect Drug Influence*
F. Tennant, Community Health Projects Medical Group, West Covina, CA
72. *Effects of Sigma Ligands on Rubral Neurons*
R. R. Matsumoto and J. M. Walker, Brown University, Providence, RI
73. *Circling Produced by Sigma Ligands via a Dopaminergic Mechanism*
R. R. Matsumoto, S. R. Goldstein, and J. M. Walker, Brown University, Providence, RI
74. *Clonidine Disrupts Long-Term Memory Processing in Mice*
A. C. Church, J. Flexner, J. E. Reynolds, Drug Enforcement Administration, Washington, D.C.
75. *Sigma Receptors Negatively Modulate Agonist-Stimulated Phosphoinositide Metabolism in Rat Brain*
W. D. Bowen, B. N. Kirschner, S. B. Hellewell, A. H. Newman, and K. C. Rice, Brown University, Providence, RI and NIDDK, NIH, Bethesda, MD

SYMPOSIUM F — 2:30 - 5:00 P.M.

AIDS and Intravenous Substance Abuse

**Chairpersons: Beny J. Primm, Don C. Des Jarlais and
Lawrence S. Brown, Jr.**

- 2:30 *AIDS and Intravenous Drug Abusers in Holland*
Roeland Coutinha, Municipal Health Services, Amsterdam, The Netherlands
- 3:00 *Preventing the Spread of HIV in Injecting Drug Users: The Experience of Syringe-Exchange Schemes in the United Kingdom*
Gerald Stimson, University of London, London, England
- 3:30 *Current Epidemiology of AIDS among Intravenous Drug Abusers in New York State*
Don C. Des Jarlais, New York State Division of Substance Abuse Services, New York, NY
- 4:00 *Role of IV Drug Use in Adolescent AIDS Cases*
Helene Gayle, Centers for Disease Control, Atlanta, GA
- 4:30 *Impact of AIDS on Health Care Delivery Systems*
Mark Smith, Robert Wood Johnson Foundation, Philadelphia, PA

2021589230

The following firms have generously supported the work of the Committee on Problems of Drug Dependence, Inc. during the past year:

**Ayerst Canada
Berlex Laboratories, Inc.
Boc Group-Anaquest
Boehringer Ingelheim International
Bristol-Myers Company
Ciba-Geigy Corporation
E.I. Du Pont de Nemours Company
H.G. Pars Pharmaceuticals
ICI Americas, Inc.
Knoll Pharmaceutical Company
Lederle Laboratories
Lilly Research Laboratories
Marion Laboratories
Merck, Sharp & Dohme Research Laboratories
Merrell Dow Pharmaceuticals
Ortho Pharmaceuticals Corporation
Reckitt & Colman, Pharmaceutical Division
Schering Corporation
Searle Research and Development
Smith, Kline and French Laboratories
Sterling Drug, Inc.
Syntex Corporation
The Upjohn Company
Warner Lambert**

2021589291

2021589293